Track topics on Twitter Track topics that are important to you
- Record Q2 2015 Total Revenue, Adjusted EBITDA and Net Income –
- Strong Q2 2015 Revenue Growth of 44.9% Over the Same Period in 2014 -
- Raises 2015 Guidance -
GOLETA, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended June 30, 2015.
Second Quarter 2015 Highlights
"Our record revenues in the second quarter reflect exceptionally strong performance across all of our sales channels, as well as the benefit of seasonality. Net income and Adjusted EBITDA also reached record levels, demonstrating our substantial operating cost leverage," said President and Chief Executive Officer, Raymond Huggenberger. "As we look out towards the second half of this year, we expect to see stronger than originally anticipated demand continue, and as a result, are updating our guidance for 2015 accordingly."
Second Quarter Financial Results
Total revenue for the three months ended June 30, 2015 rose 44.9% to $44.0 million, from $30.4 million in the second quarter of 2014. Total sales revenue in the second quarter of 2015 rose 58.3% from the second quarter of 2014. Domestic business-to-business sales grew 80.5% over the same period in 2014 and represented the fastest growing channel in the quarter, primarily due to growing reseller and private label demand for the Company's portable oxygen concentrators. International business-to-business sales grew 71.7% over the same period in 2014. International business-to-business sales continued to materially exceed the Company's expectations, in large part due to the strength of its European partners. Direct-to-consumer sales rose 35.0% over the same period in 2014, primarily due to the impact of the additional sales headcount the Company added at the end of 2014 and in the first half of 2015. Direct-to-consumer rental revenue grew 17.3% over the same period in 2014. The Company's total patient population increased by 1,600 net patients in the second quarter of 2015 compared to the first quarter of 2015. Inogen continues to shift sales capacity towards consumer sales instead of rentals, primarily due to the upcoming additional Medicare reimbursement cuts. Combined, direct-to-consumer sales and rental revenue represented more than half of our total revenue in the quarter, highlighting the strength of the Company's direct-to-consumer model and growing brand awareness.
Gross margin was $20.8 million, or 47.3% of revenue, in the second quarter of 2015 compared to $15.1 million, or 49.7% of revenue in the comparative period in 2014. Sales gross margin was $14.5 million, or 44.8% of revenue in the second quarter of 2015 versus $9.8 million, or 47.8% of revenue in the second quarter of 2014. The decline in sales gross margin percentage was primarily related to a shift in sales mix towards lower gross margin business-to-business revenue streams domestically and internationally versus direct-to-consumer revenue. In addition, while average-selling prices for direct-to-consumer increased in the second quarter of 2015 primarily due to the pricing trial conducted in the second quarter of 2014, average-selling prices declined across business-to-business sales as volume increased to resellers, private label partners, and international customers. Rental gross margin was 54.1% in the second quarter of 2015 versus 53.7% in the second quarter of 2014, primarily due to lower servicing costs of the Company's rental patients on service.
Operating expense was $15.5 million, or 35.2% of revenue, in the second quarter of 2015 versus $11.2 million, or 36.7% of revenue, in the second quarter of 2014. Research and development expense was $1.0 million in the quarter versus $0.9 million in 2014, primarily due to increased personnel-related expenses for engineering projects. Sales and marketing expense was $7.6 million in the quarter versus $6.4 million in 2014, primarily due to increased direct-to-consumer personnel-related expenses and related customer and clinical services personnel-related expenses. General and administrative expense was $6.9 million in the quarter, compared to $3.9 million in 2014. The increase was primarily related to increased legal fees and personnel-related costs. General and administrative expense for the quarter included $0.9 million in legal and accounting fees associated with the audit committee investigation and class action lawsuit that were both concluded in the second quarter of 2015. Expenses associated with the audit committee investigation and the class action lawsuit in the six-month period ended June 30, 2015 were $1.8 million. These costs are expected to be non-recurring in future periods.
Adjusted EBITDA for the three months ended June 30, 2015 rose 28.8% to $9.6 million from $7.4 million in the second quarter of 2014.
Net income for the three months ended June 30, 2015 increased 51.3% to $3.5 million from $2.3 million in the second quarter of 2014, or $0.17 per diluted common share on a GAAP basis compared to $0.11 per diluted common share on a GAAP basis in the second quarter of 2014. In the second quarter of 2015, Inogen's effective tax rate was 34.9%.
Cash, cash equivalents and short-term investments were $66.1 million as of June 30, 2015, an increase of $5.0 million in the quarter primarily due to profits, reduced working capital, and option exercises, partially offset by investments in property and equipment primarily for the Company's rental fleet additions.
Financial Outlook for 2015
Inogen is increasing its 2015 revenue guidance to a range of $145 to $149 million, which represents year-over-year growth of 28.8% to 32.4%. This compares to the previous revenue expectation of $133 to $137 million. This increase in guidance is associated with better than expected business-to-business revenue worldwide. The Company typically sees the highest revenue seasonality in the second quarter of the year when patients are more likely to travel and as a result purchase or rent its products.
The Company is also increasing its 2015 Adjusted EBITDA estimate to a range of $29 to $32 million, representing an increase of 21.1% to 33.6% over 2014. This is updated from prior guidance of $27 to $30 million.
Net income for 2015 is currently expected to be in the range of $8.5 to $10 million, representing an approximate increase of 24.5% to 46.5% over 2014. This is updated from a prior range of $8 to $9.5 million. The one-time general and administrative operating expenses of $1.8 million associated with the audit committee investigation are included in this guidance, and all expenses were incurred during the six-month period ended June 30, 2015.
The Company continues to expect an effective tax rate in 2015 of approximately 35%.
The Company also confirms its expectation of net positive cash flow for 2015 with no additional equity capital required to meet its current plan.
Individuals interested in listening to the conference call today at 1:30pm PT/4:30pm ET may do so by dialing (855) 427-4393 for domestic callers or (484) 756-4258 for international callers and reference Conference ID: 85194368. To listen to a live webcast, please visit the investor relations section of Inogen's website at: www.inogen.com.
A replay of the call will be available beginning August 11, 2015 at 3:30pm PT/6:30pm ET through midnight on August 12, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 85194368. The webcast will also be available on Inogen's website for one year following the completion of the call.
Inogen has used, and intends to continue to use, its Investor Relations website, www.inogen.com/investor, as a means of disclosing material non-public information and for complying with its disclosure obligations under the Securities and Exchange Commission's Regulation FD. For more information, including a copy of our most recent Corporate Presentation, visit www.inogen.com/investor.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Inogen's current estimates of full year 2015 revenue, Adjusted EBITDA, effective tax rate, cash flow, and net income. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates, including in connection with the implementation of the competitive bidding and the newly released Center for Medicare and Medicaid Services (CMS) rules; the possible loss of key employees, customers, or suppliers; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; its ability to successfully launch new products and applications; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2014 and in Inogen's subsequent reports on Form 10-Q and Form 8-K, filed with the Securities and Exchange Commission, including Inogen's Quarterly Report on Form 10-Q for the period ended June 30, 2015 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Use of Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and six months ended June 30, 2015 and 2014. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen's core operating results. Management uses non-GAAP measures to compare Inogen's performance relative to forecasts and strategic plans and to benchmark Inogen's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying table of this release. For future periods, Inogen is unable to provide a reconciliation of Adjusted EBITDA to net income as a result of the uncertainty regarding, and the potential variability of, the amounts of interest income, interest expense, depreciation and amortization, stock-based compensation, provisions for income taxes, and certain other infrequently occurring items, such as acquisition related costs, that may be incurred in the future.
-- Financial Tables Follow --
|(amounts in thousands)|
|June 30,||December 31,|
|Cash and cash equivalents||$51,822||$56,836|
|Deferred cost of revenue||460||515|
|Income tax receivable||2,148||2,129|
|Deferred tax asset - current||4,976||4,976|
|Prepaid expenses and other current assets||1,723||1,122|
|Total current assets||109,442||92,543|
|Property and equipment, net||32,174||31,927|
|Intangible assets, net||238||270|
|Deferred tax asset - noncurrent||15,248||15,248|
|Liabilities and stockholders' equity|
|Accounts payable and accrued expenses||$17,181||$11,273|
|Current portion of long-term debt||307||299|
|Warranty reserve - current||1,065||781|
|Total current liabilities||25,088||18,735|
|Warranty reserve - noncurrent||541||334|
|Deferred revenue - noncurrent||3,155||2,176|
|Long-term debt, net of current portion||159||315|
|Other noncurrent liabilities||339||375|
|Total stockholders' equity||127,917||118,150|
|Total liabilities and stockholders' equity||$157,199||$140,085|
|Statements of Operations|
|(amounts in thousands, except share and per share amounts)|
|Three months ended||Six months ended|
|June 30,||June 30,|
|Cost of revenue|
|Cost of sales revenue||17,866||10,682||30,455||18,223|
|Cost of rental revenue, including depreciation of $2,944 and $2,503 for three months ended and $5,900 and $4,760 for the six months ended, respectively||5,341||4,597||10,481||8,751|
|Total cost of revenue||23,207||15,279||40,936||26,974|
|Research and development||975||879||1,838||1,514|
|Sales and marketing||7,567||6,364||14,491||12,069|
|General and administrative||6,935||3,908||12,653||7,957|
|Total operating expense||15,477||11,151||28,982||21,540|
|Income from operations||5,345||3,963||7,863||5,512|
|Other income (expense)|
|Change in fair value of preferred stock warrant liability||--||--||--||36|
|Other income (expense)||(51)||4||(156)||11|
|Total other expense, net||(31)||(187)||(131)||(271)|
|Income before provision for income taxes||5,314||3,776||7,732||5,241|
|Provision for income taxes||1,855||1,490||2,701||2,067|
|Basic net income per share attributable to common stockholders||$0.18||$0.13||$0.26||$0.13|
|Diluted net income per share attributable to common stockholders||$0.17||$0.11||$0.24||$0.11|
|Weighted-average number of shares used in calculating net income per share attributable to common stockholders:|
|Basic common shares||19,310,064||18,201,661||19,239,218||13,843,803|
|Diluted common shares||20,672,414||20,146,915||20,617,342||15,826,754|
|Supplemental Financial Information|
|(in thousands, except units and patients)|
|Three months ended June 30,||Six months ended June 30,|
|Revenue by region and category|
|Business-to-business domestic sales||$9,916||$5,493||$15,796||$8,938|
|Business-to-business international sales||10,571||6,156||18,969||10,602|
|Direct-to-consumer domestic sales||11,898||8,815||20,669||15,781|
|Direct-to-consumer domestic rentals||11,644||9,929||22,347||18,705|
|Additional non-GAAP financial measures|
|Net rental patients as of period-end||31,600||25,100||31,600||25,100|
|Reconciliation of U.S. GAAP to Pro-Forma and Non-GAAP Financial Information|
|(in thousands, except share and per share amounts)|
|Three months ended June 30,||Six months ended June 30,|
|EBITDA and Adjusted EBITDA||2015||2014||2015||2014|
|Provision for income taxes||1,855||1,490||2,701||2,067|
|Depreciation and amortization||3,464||2,928||6,908||5,586|
|Change in fair value of preferred stock warrant liability||—||—||—||(36)|
|Pro-forma non-GAAP results of EPS calculation|
|Net income attributable to common stockholders before preferred rights dividend||$3,459||$2,286||$5,031||$2,187|
|Add deemed dividend on redeemable convertible preferred stock||—||—||—||987|
|Pro-forma net income||$3,459||$2,286||$5,031||$3,174|
|Pro-forma net income per share - basic common stock||$0.18||$0.13||$0.26||$0.18|
|Pro-forma net income per share - diluted common stock||$0.17||$0.11||$0.24||$0.16|
|Pro-forma weighted-average common shares - basic common stock||19,310,064||18,201,661||19,239,218||17,308,133|
|Pro-forma weighted-average common shares - diluted common stock||20,672,414||20,146,915||20,617,342||19,291,084|
CONTACT: Investor Relations Contact: firstname.lastname@example.org 805-562-0500 ext. 7 Media Contact: Byron Myers 805-562-0503NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...